Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | CDK4 | P11802 | 1/20 | 0.34 |
| ▸ | CCND1 | P24385 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 4/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | SIRT6 | Q8N6T7 | 2/20 | 0.34 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.34 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.33 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25215803 | 0.83 | CHRNB2 (0.35) | KCNH2ALDH1A1MAPTL3MBTL1 | |
| SCHEMBL26629221 | 0.83 | CHRNB2 (0.35) | KCNH2ALDH1A1MAPTL3MBTL1 | |
| SCHEMBL22652044 | 0.81 | ALDH1A1 (0.36) | KCNH2ALDH1A1MAPTCYP1A2CYP2C19 | |
| SCHEMBL22652198 | 0.81 | ALDH1A1 (0.36) | KCNH2ALDH1A1MAPTCYP1A2CYP2C19 | |
| SCHEMBL22652110 | 0.80 | MAPT (0.38) | KCNH2ALDH1A1MAPTCYP1A2CYP2C19 | |
| SCHEMBL26677915 | 0.80 | MAPT (0.38) | KCNH2ALDH1A1MAPTCYP1A2CYP2C19 | |
| SCHEMBL30411911 | 0.79 | F13A1 (0.45) | ALDH1A1MAPTHSD11B1LMNA | |
| SCHEMBL30635735 | 0.79 | F13A1 (0.45) | ALDH1A1MAPTHSD11B1LMNA | |
| SCHEMBL26165411 | 0.78 | CHRNB2 (0.58) | — | |
| SCHEMBL30900358 | 0.77 | TUBB4A (0.44) | ALDH1A1MAPTSIRT6HSD11B1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230338376-A1 | AMINOPYRIMIDINE AMIDE AUTOPHAGY INHIBITORS AND METHODS OF USE THEREOF | DECIPHERA PHARMACEUTICALS, LLC | 2023-10-26 | — | — | US | disclosed |
| US-20230338376-A1 | AMINOPYRIMIDINE AMIDE AUTOPHAGY INHIBITORS AND METHODS OF USE THEREOF | DECIPHERA PHARMACEUTICALS, LLC | 2023-10-26 | — | — | US | disclosed |
| US-11590134-B2 | Aminopyrimidine amide autophagy inhibitors and methods of use thereof | DECIPHERA PHARMACEUTICALS, LLC (US) | 2023-02-28 | — | — | US | disclosed |
| US-20230039712-A1 | PHENYLAMINOPYRIMIDINE AMIDE AUTOPHAGY INHIBITORS AND METHODS OF USE THEREOF | DECIPHERA PHARMACEUTICALS, LLC | 2023-02-09 | — | — | US | disclosed |
| US-11530206-B2 | Phenylaminopyrimidine amide autophagy inhibitors and methods of use thereof | DECIPHERA PHARMACEUTICALS, LLC (US) | 2022-12-20 | — | — | US | disclosed |
| US-20210128556-A1 | AMINOPYRIMIDINE AMIDE AUTOPHAGY INHIBITORS AND METHODS OF USE THEREOF | DECIPHERA PHARMACEUTICALS, LLC | 2021-05-06 | — | — | US | disclosed |
| US-20200354352-A1 | PHENYLAMINOPYRIMIDINE AMIDE AUTOPHAGY INHIBITORS AND METHODS OF USE THEREOF | DECIPHERA PHARMACEUTICALS, LLC | 2020-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210128556-A1 | AMINOPYRIMIDINE AMIDE AUTOPHAGY INHIBITORS AND METHODS OF USE THEREOF | BECN1, SQSTM1, ATG7 | KCNH2 4870/4885ALDH1A1 2251/4885CDK4 133/4885 |
| US-11590134-B2 | Aminopyrimidine amide autophagy inhibitors and methods of use thereof | BECN1, SQSTM1, ATG7 | KCNH2 4870/4885ALDH1A1 2251/4885CDK4 133/4885 |
| US-20230039712-A1 | PHENYLAMINOPYRIMIDINE AMIDE AUTOPHAGY INHIBITORS AND METHODS OF USE THEREOF | BECN1, SQSTM1, ATG7 | KCNH2 4864/4885ALDH1A1 2271/4885CDK4 105/4885 |
| US-11530206-B2 | Phenylaminopyrimidine amide autophagy inhibitors and methods of use thereof | BECN1, SQSTM1, ATG7 | KCNH2 4864/4885ALDH1A1 2271/4885CDK4 105/4885 |
| US-20200354352-A1 | PHENYLAMINOPYRIMIDINE AMIDE AUTOPHAGY INHIBITORS AND METHODS OF USE THEREOF | BECN1, SQSTM1, ATG7 | KCNH2 4864/4885ALDH1A1 2271/4885CDK4 105/4885 |
| US-20230338376-A1 | AMINOPYRIMIDINE AMIDE AUTOPHAGY INHIBITORS AND METHODS OF USE THEREOF | BECN1, SQSTM1, ATG7 | KCNH2 4870/4885ALDH1A1 2251/4885CDK4 133/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.